Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

By Kelland L.R.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 12, 2000-12 ,pp. : 2903-2911

Informa Healthcare

Access to resources Recommend Favorite

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

By Bose Prithviraj   Simmons Gary L   Grant Steven  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 723-738

Informa Healthcare

Access to resources Recommend Favorite

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

By Burdette-Radoux Susan   Tozer Richard   Lohmann Reinhard   Quirt Ian   Ernst D.   Walsh Wendy   Wainman Nancy   Colevas A.   Eisenhauer Elizabeth  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 315-322

Springer Publishing Company

Access to resources Recommend Favorite

Recent Advances in Cyclin-Dependent Kinase Inhibition. Purine-Based Derivatives as Anti-Cancer Agents. Roles and Perspectives for the Future

By  

Current Topics in Medicinal Chemistry, Vol. 2, Iss. 9, 2002-09 ,pp. : 1037-1050

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclin-dependent kinase inhibitors: a survey of recent patent literature

By Galons Hervé   Oumata Nassima   Meijer Laurent  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 3, 2010-03 ,pp. : 377-404

Informa Healthcare

Access to resources Recommend Favorite